List view / Grid view
Following their recent LinkedIn Live, Hexagon’s Adam Cross, Industry Director for Pharma and Life Sciences, reveals the state of data in pharmaceutical manufacturing, the opportunities available and how companies can ensure success and sustainable outcomes in their digitalisation journey.
The pharmaceutical industry faces mounting pressure to modernise its testing methods, driven by concerns over animal welfare, sustainability, and the need for more reliable results. Following a recent webinar, Fujifilm Wako discusses its Pyrostar™ Neo+ reagent and reveals how recombinant technology is transforming endotoxin testing while addressing evolving industry demands.
27 June 2025 | By Thermo Fisher Scientific
This webinar will explore how lipid formulations in softgels can enhance drug absorption and bioavailability.
The new manufacturing site features automation capabilities to ensure efficient production and supports advancement of potential next-generation microbial therapies.
The new EU rules for medicines aims to strengthen EU pharmaceutical competitiveness and reduce the regulatory burden.
Overcome matrix interferences in RNA–LNP endotoxin testing with LAL-based methods & recombinant factor C assays. Learn more in this whitepaper.
EPR Issue 1 includes articles on manufacturing, drug delivery, process analytical technology (PAT), RNA therapeutics and more.
7 March 2025 | By Fujifilm Wako
Discover the benefits of sustainable recombinant LAL for endotoxin testing. Learn about its relevance, selection considerations, and seamless integration into your lab processes with expert insights.
The innovative artificial photosynthesis technique offers a new approach to eco-friendly chemical production.
The new digitally-led centre will help to accelerate economic growth and productivity in process manufacturing, while supporting a sustainable future in Scotland.
The cleaner method could significantly lower production costs and reduce carbon dioxide emissions resulting from ethylene oxide manufacturing.
The breakthrough promises to transform pharmaceutical manufacturing by enabling chemical reactions in water, reducing reliance on hazardous organic solvents.
As a significant water consumer to enable production of high-quality medicines, this demand brings both challenges and opportunities for the pharmaceutical industry up to 2033, research suggests.
The directive could lead to nearly €1 billion in additional costs for pharmaceutical companies in Finland alone, states Orion Corporation.
Sarah Moores, Global Sustainability Director at AstraZeneca, discusses the potential scope for establishing electronic product information (ePI) in the pharmaceutical industry to support its endeavours in environmental sustainability.
